---
title: "MoonLake Q2 FY26 net loss widens 10.3% to $61.81 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295402045.md"
description: "MoonLake Immunotherapeutics reported a Q2 FY26 net loss of $61.81 million, widening 10.3% year-over-year. Operating losses increased to $61.66 million due to higher R&D and administrative costs, while other income dropped significantly. The company holds $537 million in cash, sufficient for operations through mid-2028. MoonLake aims to submit a BLA for sonelokimab for hidradenitis suppurativa by the end of Q3 2026, targeting a U.S. launch in H2 2027."
datetime: "2026-08-10T11:50:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295402045.md)
  - [en](https://longbridge.com/en/news/295402045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295402045.md)
generator: "portal-rs"
---

# MoonLake Q2 FY26 net loss widens 10.3% to $61.81 million

-   MoonLake Immunotherapeutics posted a net loss of $61.81 million, widening 10.3% year over year in the quarter ended June 30, 2026. \* Operating loss widened 1.6% to $61.66 million as research and development spending edged up 0.9% to $50.22 million. \* General and administrative costs rose 4.6% to $11.44 million, while other income fell 62% to $2.58 million. \* Cash, cash equivalents, and short-term marketable securities totaled $537 million at June 30, funding operations to mid-2028. \* MoonLake targets a BLA submission for sonelokimab in hidradenitis suppurativa at end-Q3 2026, aiming for a U.S. launch in H2 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001821586-26-000010), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)

## Related News & Research

- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Plazza posts H1 2026 interim report online](https://longbridge.com/en/news/296736136.md)
- [BetterLife Pharma delays annual general meeting to Oct. 14, 2026](https://longbridge.com/en/news/296799901.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Andfjord Salmon schedules Q2/H1 2026 results webcast and operational update](https://longbridge.com/en/news/296742723.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**